Clinical Trial: A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors

U.S., July 29 -- ClinicalTrials.gov registry received information related to the study (NCT07730021) titled 'A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors' on July 23.

Brief Summary: This is an early development study of ASP388B in people with solid tumors. In this study, ASP388B will be given to people for the first time. It will be given by itself or together with standard cancer therapies. The main aims of the study are to check the safety of ASP388B and find the most suitable dose.

This study will be in 2 parts. In Part 1, different small groups of people with solid tumors will receive lower to higher doses of ASP388B. Some groups will receive ASP388B by itself, and other groups will ...